Fabentech

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fabentech aims to provide therapeutic solutions in the fields...

Immunotherapy,polyclonal,antibody,antibodies,emergency,antidote,antitoxin,bioterrorism,bioweapon,poison,infectious disease,infectious diseases,nosocomial,emerging,epidemic,pandemic,ebola,drug abuse,and narcotic dependence

Fabentech operates in the Pharmaceutical manufacturing industry.

Fabentech's revenue is 11m - 100m

Fabentech has 51 - 200 employees.